Can-Fite BioPharma (NYSE:CANF) Earns Sell Rating from Analysts at StockNews.com
Equities researchers at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock. Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma […]
Equities researchers at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF – Get Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock. Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Can-Fite BioPharma […]
